Free Trial

Enovis (ENOV) Stock Price, News & Analysis

$50.56
-0.59 (-1.15%)
(As of 02:38 PM ET)
Today's Range
$50.51
$51.31
50-Day Range
$50.55
$62.45
52-Week Range
$43.04
$66.14
Volume
138,907 shs
Average Volume
488,721 shs
Market Capitalization
$2.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$75.43

Enovis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
48.4% Upside
$75.43 Price Target
Short Interest
Bearish
8.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Enovis in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
17.18%
From $2.62 to $3.07 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.15 out of 5 stars

Medical Sector

332nd out of 921 stocks

Surgical Appliances & Supplies Industry

10th out of 18 stocks

ENOV stock logo

About Enovis Stock (NYSE:ENOV)

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

ENOV Stock Price History

ENOV Stock News Headlines

Enovis Announces First Quarter 2024 Results
Arcuro Medical Appoints Jamal Rushdy CEO
ENOV Dec 2024 60.000 put
ENOV Mar 2024 60.000 put
ENOV Jun 2024 50.000 put
See More Headlines
Receive ENOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/02/2024
Today
5/21/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
N/A
Employees
6,550
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$75.43
High Stock Price Target
$82.00
Low Stock Price Target
$70.00
Potential Upside/Downside
+48.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-33,260,000.00
Pretax Margin
-6.41%

Debt

Sales & Book Value

Annual Sales
$1.71 billion
Cash Flow
$6.22 per share
Book Value
$62.66 per share

Miscellaneous

Free Float
53,535,000
Market Cap
$2.79 billion
Optionable
Optionable
Beta
1.99
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

ENOV Stock Analysis - Frequently Asked Questions

Should I buy or sell Enovis stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ENOV shares.
View ENOV analyst ratings
or view top-rated stocks.

What is Enovis' stock price target for 2024?

8 Wall Street analysts have issued 12-month price objectives for Enovis' stock. Their ENOV share price targets range from $70.00 to $82.00. On average, they predict the company's stock price to reach $75.43 in the next twelve months. This suggests a possible upside of 48.4% from the stock's current price.
View analysts price targets for ENOV
or view top-rated stocks among Wall Street analysts.

How have ENOV shares performed in 2024?

Enovis' stock was trading at $56.02 at the beginning of the year. Since then, ENOV shares have decreased by 9.3% and is now trading at $50.83.
View the best growth stocks for 2024 here
.

Are investors shorting Enovis?

Enovis saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 4,440,000 shares, an increase of 6.5% from the April 15th total of 4,170,000 shares. Based on an average daily trading volume, of 491,000 shares, the short-interest ratio is currently 9.0 days. Currently, 8.2% of the company's stock are short sold.
View Enovis' Short Interest
.

When is Enovis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our ENOV earnings forecast
.

How were Enovis' earnings last quarter?

Enovis Co. (NYSE:ENOV) announced its quarterly earnings data on Thursday, May, 2nd. The company reported $0.50 EPS for the quarter, hitting the consensus estimate of $0.50. The business had revenue of $516 million for the quarter, compared to analysts' expectations of $505.62 million. Enovis had a negative net margin of 4.51% and a positive trailing twelve-month return on equity of 3.98%. The business's revenue was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.44 earnings per share.

What ETFs hold Enovis' stock?

ETFs with the largest weight of Enovis (NYSE:ENOV) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE) and Principal Healthcare Innovators ETF (BTEC).iShares U.S. Medical Devices ETF (IHI).

What guidance has Enovis issued on next quarter's earnings?

Enovis updated its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of 2.520-2.670 for the period, compared to the consensus estimate of 2.600. The company issued revenue guidance of $2.1 billion-$2.2 billion, compared to the consensus revenue estimate of $2.1 billion.

Who are Enovis' major shareholders?

Enovis' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.92%), DAVENPORT & Co LLC (3.61%), Allspring Global Investments Holdings LLC (1.84%), Allspring Global Investments Holdings LLC (1.84%), Principal Financial Group Inc. (1.55%) and Magnetar Financial LLC (1.21%). Insiders that own company stock include A Clayton Perfall, Bradley J Tandy, Brady Shirley, Christopher M Hix, Daniel A Pryor, John Kleckner, Matthew L Trerotola, Patricia A Lang, Phillip Benjamin (Ben) Berry and Rajiv Vinnakota.
View institutional ownership trends
.

How do I buy shares of Enovis?

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ENOV) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners